by The global pharmaceutical CDMO market size accounted for US$ 94.17 Bn in 2022 and is projected to reach around USD 172.02 Bn by 2032, growing at a CAGR of 6.21% from 2023 to 2032.
Report Summary
The global pharmaceutical CDMO market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.
The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the pharmaceutical CDMO market across the globe.
A comprehensive estimate on the pharmaceutical CDMO market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of pharmaceutical CDMO during the forecast period. Price point comparison by region with global average price is also considered in the study.
Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2936
Pharmaceutical CDMO Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 100.02 Billion |
| Market Size by 2032 | USD 172.02 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 6.21% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Product, By Drug Product, By Dosage Form, By Indication, and By End-User |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
Key Highlights:
Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized pharmaceutical CDMO market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.
Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.
Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.
Also Read: Anti-Aging Cosmetics Market Size Analysis 2023 To 2032
Pharmaceutical CDMO Market Players
The report includes the profiles of key pharmaceutical CDMO market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.
Major companies operating in this area
- Bushu Pharmaceuticals Ltd.
- Nipro Corporation
- Thermo Fisher Scientific Inc.
- Samsung Biologics
- Laboratory Corporation of America Holdings
- Siegfried Holding Ag
- Catalent, Inc
- Lonza Group AG
- Recipharm Ab
- Piramal Pharma Solutions
- Cordenpharma International
- Cambrex Corporation
- Wuxi Apptec
Market Segmentation
By Product
- API
- By Synthetic
- Solid
- Liquid
- By Type
- Traditional Active Pharmaceutical Ingredient (Traditional API)
- Highly Potent Active Pharmaceutical Ingredient (HP-API)
- Antibody Drug Conjugate (ADC)
- Others
- By Drug
- Innovative
- Generics
- By Manufacturing
- Continuous manufacturing
- Batch manufacturing
- Biotech
- By Synthetic
By Drug Product
- Oral Solid Dose
- Semi-solid dose
- Liquid Dose
- Others
By Dosage Form
- Solid
- Tablets
- Capsules
- Powder
- Semi-Solid
- Cream
- Paste
- Gel
- Liquid Dose Formulation
- Injectables
- Sterile Vials
- Single Use/Single Dose
- Multi-Use
- Ampules
- Prefilled Syringes
- Suspension
- Emulsion
- Gas Dose Formulation
- Inhaler
- Aerosols
By Indication
- Cancer
- Cardiovascular Disease
- Diabetes
- Pain
- Respiratory disease
- Other Disease
By End-User
- Big Pharmaceutical Companies
- Small & Medium-Sized Pharmaceutical Companies
- Generic Pharmaceutical Companies
- Other End Users
Regional Segmentation
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Research Methodology
Secondary Research
It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.
The secondary research sources referred in the process are as follows:
- Governmental bodies, and organizations creating economic policies
- National and international social welfare institutions
- Company websites, financial reports and SEC filings, broker and investor reports
- Related patent and regulatory databases
- Statistical databases and market reports
- Corporate Presentations, news, press release, and specification sheet of Manufacturers
Primary Research
Primary research includes face-to-face interviews, online surveys, and telephonic interviews.
- Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
- In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Pharmaceutical CDMO Market
5.1. COVID-19 Landscape: Pharmaceutical CDMO Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Pharmaceutical CDMO Market, By Product
8.1. Pharmaceutical CDMO Market, by Product, 2023-2032
8.1.1. API
8.1.1.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Pharmaceutical CDMO Market, By Drug Product
9.1. Pharmaceutical CDMO Market, by Drug Product, 2023-2032
9.1.1. Oral Solid Dose
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Semi-solid dose
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Liquid Dose
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Pharmaceutical CDMO Market, By Dosage Form
10.1. Pharmaceutical CDMO Market, by Dosage Form, 2023-2032
10.1.1. Solid
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Semi-Solid
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Liquid Dose Formulation
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Gas Dose Formulation
10.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Pharmaceutical CDMO Market, By Indication
11.1. Pharmaceutical CDMO Market, by Indication, 2023-2032
11.1.1. Cancer
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Cardiovascular Disease
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Diabetes
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. Pain
11.1.4.1. Market Revenue and Forecast (2020-2032)
11.1.5. Respiratory disease
11.1.5.1. Market Revenue and Forecast (2020-2032)
11.1.6. Other Disease
11.1.6.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Pharmaceutical CDMO Market, By End-User
12.1. Pharmaceutical CDMO Market, by End-User, 2023-2032
12.1.1. Big Pharmaceutical Companies
12.1.1.1. Market Revenue and Forecast (2020-2032)
12.1.2. Small & Medium-Sized Pharmaceutical Companies
12.1.2.1. Market Revenue and Forecast (2020-2032)
12.1.3. Generic Pharmaceutical Companies
12.1.3.1. Market Revenue and Forecast (2020-2032)
12.1.4. Other End Users
12.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 13. Global Pharmaceutical CDMO Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Product (2020-2032)
13.1.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.1.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.1.4. Market Revenue and Forecast, by Indication (2020-2032)
13.1.5. Market Revenue and Forecast, by End-User (2020-2032)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.1.6.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.1.6.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.1.6.4. Market Revenue and Forecast, by Indication (2020-2032)
13.1.6.5. Market Revenue and Forecast, by End-User (2020-2032)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Product (2020-2032)
13.1.7.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.1.7.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.1.7.4. Market Revenue and Forecast, by Indication (2020-2032)
13.1.7.5. Market Revenue and Forecast, by End-User (2020-2032)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.2.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.2.4. Market Revenue and Forecast, by Indication (2020-2032)
13.2.5. Market Revenue and Forecast, by End-User (2020-2032)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.6.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.2.6.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.2.7. Market Revenue and Forecast, by Indication (2020-2032)
13.2.8. Market Revenue and Forecast, by End-User (2020-2032)
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.9.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.2.9.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.2.10. Market Revenue and Forecast, by Indication (2020-2032)
13.2.11. Market Revenue and Forecast, by End-User (2020-2032)
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.12.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.2.12.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.2.12.4. Market Revenue and Forecast, by Indication (2020-2032)
13.2.13. Market Revenue and Forecast, by End-User (2020-2032)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Product (2020-2032)
13.2.14.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.2.14.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.2.14.4. Market Revenue and Forecast, by Indication (2020-2032)
13.2.15. Market Revenue and Forecast, by End-User (2020-2032)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.3.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.3.4. Market Revenue and Forecast, by Indication (2020-2032)
13.3.5. Market Revenue and Forecast, by End-User (2020-2032)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.6.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.3.6.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.3.6.4. Market Revenue and Forecast, by Indication (2020-2032)
13.3.7. Market Revenue and Forecast, by End-User (2020-2032)
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.8.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.3.8.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.3.8.4. Market Revenue and Forecast, by Indication (2020-2032)
13.3.9. Market Revenue and Forecast, by End-User (2020-2032)
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.10.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.3.10.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.3.10.4. Market Revenue and Forecast, by Indication (2020-2032)
13.3.10.5. Market Revenue and Forecast, by End-User (2020-2032)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Product (2020-2032)
13.3.11.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.3.11.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.3.11.4. Market Revenue and Forecast, by Indication (2020-2032)
13.3.11.5. Market Revenue and Forecast, by End-User (2020-2032)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.4.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.4.4. Market Revenue and Forecast, by Indication (2020-2032)
13.4.5. Market Revenue and Forecast, by End-User (2020-2032)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.6.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.4.6.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.4.6.4. Market Revenue and Forecast, by Indication (2020-2032)
13.4.7. Market Revenue and Forecast, by End-User (2020-2032)
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.8.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.4.8.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.4.8.4. Market Revenue and Forecast, by Indication (2020-2032)
13.4.9. Market Revenue and Forecast, by End-User (2020-2032)
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.10.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.4.10.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.4.10.4. Market Revenue and Forecast, by Indication (2020-2032)
13.4.10.5. Market Revenue and Forecast, by End-User (2020-2032)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Product (2020-2032)
13.4.11.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.4.11.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.4.11.4. Market Revenue and Forecast, by Indication (2020-2032)
13.4.11.5. Market Revenue and Forecast, by End-User (2020-2032)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Product (2020-2032)
13.5.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.5.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.5.4. Market Revenue and Forecast, by Indication (2020-2032)
13.5.5. Market Revenue and Forecast, by End-User (2020-2032)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Product (2020-2032)
13.5.6.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.5.6.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.5.6.4. Market Revenue and Forecast, by Indication (2020-2032)
13.5.7. Market Revenue and Forecast, by End-User (2020-2032)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Product (2020-2032)
13.5.8.2. Market Revenue and Forecast, by Drug Product (2020-2032)
13.5.8.3. Market Revenue and Forecast, by Dosage Form (2020-2032)
13.5.8.4. Market Revenue and Forecast, by Indication (2020-2032)
13.5.8.5. Market Revenue and Forecast, by End-User (2020-2032)
Chapter 14. Company Profiles
14.1. Bushu Pharmaceuticals Ltd.
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Nipro Corporation
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Thermo Fisher Scientific Inc.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Samsung Biologics
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Laboratory Corporation of America Holdings
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Siegfried Holding Ag
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Catalent, Inc
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Lonza Group AG
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Recipharm Ab
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Piramal Pharma Solutions
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
